Results 21 to 30 of about 182,514 (265)

Immune checkpoint inhibitors in malignancy [PDF]

Australian Prescriber, 2019
Immune checkpoints normally stop the body from mounting an immune response against healthy cells. Some cancers can acquire these checkpoints so that the tumour cells are not recognised by the immune systemInhibiting the checkpoints therefore enables the tumour cells to be recognised and allows an immune response to be activated against themImmune ...
Luke, Ardolino, Anthony, Joshua
openaire   +2 more sources

Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model. [PDF]

PLoS ONE, 2018
Oncolytic virus (OV) is a replication competent virus that selectively invades cancer cells; as these cells die under the viral burden, the released virus particles proceed to infect other cancer cells.
Avner Friedman, Xiulan Lai
doaj   +1 more source

Immune checkpoint inhibitor myocarditis: a systematic case study

Российский кардиологический журнал, 2020
Myocarditis is a life-threatening complication of immune checkpoint inhibitor therapy. Over the past ten years, drugs in this group have been used in the treatment of a wide range of hematological diseases and solid tumors.
E. A. Kushnareva, O. M. Moiseeva
doaj   +1 more source

Longitudinal observation of insulin secretory ability before and after the onset of immune checkpoint inhibitor‐induced diabetes mellitus: A report of two cases

Clinical Case Reports, 2021
Immune checkpoint inhibitor‐induced diabetes mellitus is a rare immune‐related adverse event. This report illustrates clinical data and insulin secretory ability before and after the onset of immune checkpoint inhibitor‐induced diabetes.
Noriko Fujiwara, Mayu Watanabe, Akihiro Katayama, Yohei Noda, Jun Eguchi, Hitomi Kataoka, Shunsuke Kagawa, Jun Wada   +7 more
doaj   +1 more source

Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer

Scientific Reports, 2023
Immune checkpoint inhibitors have significantly improved the prognosis in patients with non-small cell lung cancer, compared with cytotoxic agents.
Minehiko Inomata, Masahiro Matsumoto, Naoki Takata, Kana Hayashi, Zenta Seto, Takahiro Hirai, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara, Shingo Imanishi, Toshiro Miwa, Ryuji Hayashi, Shoko Matsui, Kazuyuki Tobe   +14 more
doaj   +1 more source

Gut microbiota shed new light on the management of immune‐related adverse events

Thoracic Cancer, 2022
Immunotherapy has dramatically revolutionized the therapeutic landscape for patients with cancer. Although immune checkpoint inhibitors are now accepted as effective anticancer therapies, they introduce a novel class of toxicity, termed immune‐related ...
Bei Tan, Yun‐xin Liu, Hao Tang, Dan Chen, Yan Xu, Min‐jiang Chen, Yue Li, Meng‐zhao Wang, Jia‐ming Qian   +8 more
doaj   +1 more source

Gene signature reveals decreased SOX10-dependent transcripts in malignant cells from immune checkpoint inhibitor-resistant cutaneous melanomas

iScience, 2023
Summary: Evidence is mounting for cross-resistance between immune checkpoint and targeted kinase inhibitor therapies in cutaneous melanoma patients. Since the loss of the transcription factor, SOX10, causes tolerance to MAPK pathway inhibitors, we used ...
Timothy J. Purwin, Signe Caksa, Ahmet Sacan, Claudia Capparelli, Andrew E. Aplin   +4 more
doaj   +1 more source

Immune checkpoint inhibitors [PDF]

Journal of Cell Biology, 2019
Hui details the cell biology underlying the action of immune checkpoint inhibitors.
openaire   +4 more sources

Cardiotoxicity of Immune Checkpoint Inhibitors [PDF]

Current Oncology Reports, 2021
Immune checkpoint inhibitors (ICIs) have improved the survival of several cancers. However, they may cause a wide range of immune-related adverse events (irAEs). While most irAEs are manageable with temporary cessation of ICI and immunosuppression, cardiovascular toxicity can be associated with high rates of morbidity and mortality.
Rushin P. Patel, Rohan Parikh, Krishna S. Gunturu, Rana Zouveenoor Tariq, Sourbha S. Dani, Sarju Ganatra, Anju Nohria   +6 more
openaire   +2 more sources

Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation

Pulmonary Circulation, 2021
Immunologic risk factors contribute to endothelial dysfunction and development of pulmonary vascular disease. Immune checkpoint inhibitors, used as immunotherapies for malignancies, have a wide range of reported immune-related adverse events.
Ruben Mylvaganam, Ryan Avery, Isaac Goldberg, Courtney Makowski, Ravi Kalhan, Victoria Villaflor, Michael J. Cuttica   +6 more
doaj   +1 more source